List of Excipients in Branded Drug CLINDAMYCIN IN 5 PERCENT DEXTROSE

Generic Drugs Containing CLINDAMYCIN IN 5 PERCENT DEXTROSE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	clindamycin in percent dextrose	0143-9267	DEXTROSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	clindamycin in percent dextrose	0143-9267	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	clindamycin in percent dextrose	0143-9267	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	clindamycin in percent dextrose	0143-9267	SODIUM HYDROXIDE
Sandoz Inc	clindamycin in 5 percent dextrose	0781-3288	DEXTROSE MONOHYDRATE
Sandoz Inc	clindamycin in 5 percent dextrose	0781-3288	EDETATE DISODIUM
Sandoz Inc	clindamycin in 5 percent dextrose	0781-3288	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in CLINDAMYCIN IN 5 PERCENT DEXTROSE?

# Of NDCs	Excipient
4	DEXTROSE MONOHYDRATE
4	EDETATE DISODIUM
4	HYDROCHLORIC ACID
4	SODIUM HYDROXIDE

Clindamycin in 5% Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

Clindamycin phosphate in 5% dextrose injection is a mature sterile injectable opportunity with low active-ingredient patent risk and meaningful differentiation potential in ready-to-use packaging, stability, supply reliability, and hospital workflow. The core formulation is simple: clindamycin phosphate, dextrose, and water for injection, with limited need for additional excipients. Commercial value depends more on manufacturing execution, container technology, presentations, and procurement access than on novel chemistry.

What is clindamycin in 5% dextrose injection?

Clindamycin in 5% dextrose is an intravenous infusion product containing clindamycin phosphate diluted in dextrose injection. A 5% dextrose solution contains approximately 50 mg/mL dextrose before addition of the drug.

Clindamycin phosphate is a water-soluble prodrug converted in vivo to active clindamycin. The injection is used for serious bacterial infections caused by susceptible organisms, including selected anaerobic infections, skin and soft-tissue infections, bone and joint infections, and gynecologic or intra-abdominal infections. It is not interchangeable with clindamycin hydrochloride capsules or oral solution because the dosage form, route, strength, and excipient profile differ.

Typical clinical administration requires dilution and controlled infusion. The FDA labeling for clindamycin phosphate injection limits the infusion concentration and rate. A commonly cited maximum concentration is 18 mg/mL, with an infusion rate not exceeding 30 mg per minute.[1]

Common presentation concepts

Presentation concept	Drug load	Approximate final volume	Commercial use
Low-dose premix	300 mg	50 mL	General inpatient use
Standard premix	600 mg	50 mL	Common adult dosing
High-dose premix	900 mg	50 mL or 100 mL	Hospital and perioperative use
Extended-volume premix	1,200 mg	100 mL	High-dose adult treatment

Actual commercial presentations vary by manufacturer, container, and market. A proposed product must align its concentration and infusion instructions with the applicable reference labeling.

What excipients are used in clindamycin in 5% dextrose?

The core excipient system is narrow. The principal ingredients are dextrose and water for injection. Some products may use pH adjusters or container-contact materials that are not declared as formulation excipients in the same manner as active ingredients.

Core excipient strategy

Component	Function	Key development issue
Dextrose	Diluent and carbohydrate source	Osmolality, glycemic burden, chemical stability
Water for injection	Solvent	Sterility, endotoxin control, particulate control
pH adjuster, if used	Controls product pH	Must not create precipitation or accelerate degradation
Bag or vial materials	Primary container system	Adsorption, extractables, leachables, seal integrity
Overwrap	Protects flexible container	Moisture and oxygen barrier

The strongest formulation strategy is usually excipient minimization. Extra buffers, antioxidants, chelators, surfactants, or preservatives may create more regulatory and compatibility risk than commercial value.

Why dextrose is commercially relevant

Dextrose is familiar to hospitals and widely available in parenteral nutrition and infusion supply chains. It supports a ready-to-use premix format that eliminates bedside dilution. That can reduce pharmacy preparation time, handling steps, and medication-error opportunities.

The tradeoff is that dextrose is not clinically neutral for every patient. Patients with diabetes, hyperglycemia, impaired glucose tolerance, or certain critical-care conditions may be better served by a sodium chloride presentation or another compatible diluent. A dual-product portfolio using both 5% dextrose and 0.9% sodium chloride can expand formulary access.

What formulation properties should manufacturers optimize?

The main technical targets are chemical stability, physical compatibility, sterility assurance, container performance, and convenient administration.

Chemical stability

Development programs should evaluate:

• Clindamycin potency over labeled shelf life.
• Degradation products and impurity profile.
• pH drift.
• Color change.
• Dextrose degradation products.
• Stability after removal from controlled storage.
• In-use stability during simulated administration.
• Freeze-thaw and elevated-temperature excursions.

Dextrose solutions can undergo degradation under heat and prolonged storage. The product should be assessed under accelerated and stress conditions, including light and oxygen exposure. The formulation should also be evaluated after terminal sterilization or aseptic processing, depending on the manufacturing route.

Physical compatibility

The FDA labeling identifies incompatibilities with several injectable medicines, including ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate.[1] Compatibility is concentration-, temperature-, time-, and container-dependent.

A commercial product should carry clear instructions stating that clindamycin infusion should not be mixed in the same solution with incompatible medicines. Y-site compatibility data can support hospital adoption, but direct admixture claims require product-specific evidence.

Container selection

Container strategy can provide more differentiation than a new excipient system.

Container option	Advantages	Constraints
Flexible non-PVC bag	Lower concern over PVC-related extractables; familiar hospital workflow	Higher development and seal-integrity burden
PVC bag	Established manufacturing base and lower unit cost	DEHP and extractables scrutiny; institutional preferences vary
Glass vial	Strong barrier properties; conventional regulatory pathway	Requires pharmacy dilution; higher handling burden
Plastic vial	Lower breakage risk and light weight	Sorption, permeability, and closure compatibility require assessment
Ready-to-use bag with overwrap	Simplifies administration and protects shelf life	Packaging cost and distribution volume increase

For a new entrant, a non-PVC, ready-to-use bag with clear labeling and a tamper-evident overwrap is a commercially credible premium position. A low-cost PVC presentation may compete more effectively in commodity tenders but can face hospital restrictions.

What patents protect clindamycin in 5% dextrose?

The original clindamycin compound and early pharmaceutical patents are long expired. Clindamycin phosphate injection is a mature generic product, and no meaningful active-ingredient patent barrier generally prevents entry into the U.S. market.

The practical IP analysis has four layers:

1. Compound and salt patents.
2. Injectable formulation patents.
3. Premixed bag or container patents.
4. Manufacturing, sterilization, and packaging claims.

Patent risk by category

IP category	Commercial relevance	Expected barrier
Clindamycin compound patents	Historical only	Low
Clindamycin phosphate salt patents	Historical only	Low
Generic injectable formulation claims	Product-specific	Low to moderate
Ready-to-use premix claims	May cover concentration, stability, or packaging	Moderate if narrowly drafted
Container and closure claims	May affect bag design	Moderate
Manufacturing process claims	Can affect process replication	Usually manageable
Method-of-use patents	Limited relevance for established antibacterial uses	Low

A manufacturer should search the current FDA Orange Book, USPTO records, and relevant national registers before launch. The Orange Book identifies approved drug products, patent listings, and certain exclusivity information, but it does not provide a complete freedom-to-operate analysis for every manufacturing or packaging feature.[2]

When does clindamycin in 5% dextrose lose exclusivity?

Clindamycin in 5% dextrose has already passed the period of originator exclusivity associated with the active ingredient. Commercial entry is therefore governed primarily by approval status, manufacturing capacity, quality performance, procurement contracts, and any product-specific patents.

Exclusivity timeline

Milestone	Status
Original clindamycin discovery and early patents	Expired
Clindamycin phosphate injectable products	Mature market
New chemical entity exclusivity	Expired
Generic injectable approvals	Established
Biosimilar exclusivity	Not applicable
Current commercial barrier	Regulatory, manufacturing, and contracting execution

There is no biosimilar pathway for clindamycin because clindamycin is a small-molecule antibacterial, not a biologic. An applicant would generally pursue an abbreviated new drug application when it can demonstrate pharmaceutical equivalence and bioequivalence requirements applicable to the injectable product. A reformulated or materially differentiated product may require a 505(b)(2) application or another jurisdiction-specific pathway.

What is the Orange Book status of clindamycin phosphate injection?

Clindamycin phosphate injection products are generally treated as approved generic injectable drug products rather than protected branded innovations. The Orange Book remains the principal U.S. reference for listed patents, therapeutic-equivalence codes, and exclusivity information.[2]

For a proposed product, the regulatory team should confirm:

• Reference-listed drug selection.
• Dosage form and route.
• Strength and concentration.
• Therapeutic-equivalence requirements.
• Listed patents and certifications.
• Drug master file status for critical components.
• Product-specific labeling differences.
• Suitability of a premix presentation for ANDA submission.

Paragraph IV risk is usually limited for this mature product unless a current, listed patent covers a specific concentration, formulation, container, or manufacturing feature. A paragraph IV certification can still be required if a listed patent is relevant to the proposed product. Any such certification can trigger the statutory 30-month stay if the patent holder files suit within the applicable period.[3]

Which companies are challenging or competing with clindamycin premix products?

Competition comes from three groups:

1. Generic injectable manufacturers.
2. Contract development and manufacturing organizations.
3. Hospitals and pharmacies that dilute bulk clindamycin injection internally.

Relevant competitive products may be sold under clindamycin phosphate injection labels by companies such as Pfizer, Fresenius Kabi, Hikma, Sagent, and other generic suppliers, depending on the market and current supply status. The competitive set changes with shortages, discontinuations, manufacturing transfers, and procurement awards.

The principal substitutes are not limited to other clindamycin products. Hospital formularies may substitute:

• Vancomycin.
• Metronidazole.
• Ampicillin-sulbactam.
• Piperacillin-tazobactam.
• Cefazolin or other beta-lactams where clinically appropriate.

Clinical substitution is constrained by antimicrobial stewardship, resistance, allergy history, infection site, and pathogen susceptibility. Clindamycin remains commercially relevant where anaerobic coverage, toxin suppression, or beta-lactam avoidance is clinically preferred.

What commercial opportunities exist for clindamycin in 5% dextrose?

Ready-to-use hospital premix

The strongest opportunity is a ready-to-administer bag that eliminates pharmacy dilution. A product can compete on:

• Reduced preparation time.
• Standardized dose and concentration.
• Lower compounding workload.
• Bar-code medication administration.
• Clear infusion instructions.
• Extended supply reliability.
• Non-PVC packaging.

The product should target hospitals that have centralized pharmacy operations, high emergency-department volume, or limited sterile-compounding capacity.

Contract manufacturing and private-label supply

A manufacturer with sterile fill-finish capacity can offer private-label clindamycin premix products to distributors, group purchasing organizations, and regional hospital networks. The active ingredient is widely known, so the value proposition rests on:

• Reliable API sourcing.
• Validated aseptic processing.
• Redundant suppliers for dextrose and bags.
• Short lead times.
• Multi-dose presentation planning.
• Regulatory support for customer-specific labels.

Shortage-resilient supply

Sterile injectable markets are vulnerable to shortages caused by facility shutdowns, container constraints, and quality remediation. A supplier with dual fill-finish sites and multiple qualified bag vendors can command higher strategic value even without patent protection.

Pediatric and lower-volume presentations

Smaller-volume bags may reduce waste for pediatric and lower-dose patients. Commercial development should not assume that a single adult presentation covers all hospital needs. Dose flexibility can be created through multiple strengths, but each additional SKU raises validation, inventory, and regulatory costs.

International markets

Outside the United States, the opportunity may be stronger where hospitals rely on imported sterile injectables and local premix availability is limited. Geographic expansion requires review of:

• Local injectable registration requirements.
• Dextrose labeling conventions.
• Container standards.
• Pharmacopoeial specifications.
• Local procurement rules.
• Serialization and traceability requirements.
• Import dependence for clindamycin phosphate API.

How strong is the patent estate for clindamycin in 5% dextrose?

The patent estate is weak at the molecule level and potentially moderate at the product-system level.

A defensible new patent position would need to claim a specific technical result, such as:

• A defined clindamycin concentration in dextrose with improved stability.
• A container composition that reduces adsorption or leachables.
• A validated sterilization and packaging sequence.
• A specific overwrap or oxygen-control system.
• A stable ready-to-use formulation with defined impurity limits.
• A manufacturing process that improves shelf life or reduces particulate formation.

Broad claims covering "clindamycin in dextrose" are unlikely to provide durable protection in a mature field. Trade secrets and process know-how may be more valuable than composition claims, particularly for aseptic processing, bag sealing, oxygen control, and stability management.

What litigation and settlement risks affect generic entry?

There is no inherent litigation barrier from clindamycin's expired core patents. Litigation risk would arise from a current patent listed against the selected reference product or from disputes involving container technology, formulation claims, or manufacturing processes.

A realistic launch assessment should examine:

• Current Orange Book patent listings.
• ANDA applicant certifications.
• Paragraph IV notices.
• Any 30-month stay.
• Patent expiration and pediatric extensions.
• Settlement restrictions.
• Supply agreements and authorized-generic arrangements.
• Antitrust implications of delayed-entry agreements.

For this product, non-patent risks may be more material. These include FDA complete-response letters, sterile manufacturing observations, particulate complaints, container defects, and supply interruptions.

How should an excipient and product-development program be structured?

A commercially efficient program would use a narrow formulation design space:

1. Start with clindamycin phosphate in 5% dextrose without unnecessary additives.
2. Screen container materials and closure systems early.
3. Compare PVC and non-PVC bags.
4. Establish concentration and infusion-rate labeling.
5. Run compatibility studies against high-use hospital medicines.
6. Conduct extractables and leachables testing.
7. Build accelerated and long-term stability data.
8. Validate aseptic or terminal-sterilization operations.
9. Design at least one standard adult presentation and one smaller-volume option.
10. Protect process and packaging improvements through patents and trade secrets.

The preferred commercial target is a stable, non-PVC, ready-to-use premix with strong supply continuity and hospital-friendly labeling. The lowest-cost product can compete in tenders, while a differentiated product can pursue premium positioning through packaging, shelf life, and workflow benefits.

Key Takeaways

• Clindamycin in 5% dextrose is a mature generic injectable market with no meaningful molecule-level exclusivity.
• The core excipient system is simple: dextrose and water for injection, with limited justification for additional excipients.
• Ready-to-use premix bags offer the clearest commercial opportunity.
• Non-PVC packaging, container compatibility, shelf life, and supply reliability can differentiate the product.
• Dextrose-based products should be complemented by saline-based presentations for patients where glucose administration is undesirable.
• Paragraph IV risk is generally product-specific and depends on current Orange Book listings.
• Biosimilar risk does not apply because clindamycin is a small-molecule drug.
• Manufacturing execution, sterile quality, and procurement access are likely to matter more than legacy patent rights.
• Strong new IP would need to cover a defined formulation, container, stability result, or manufacturing process rather than clindamycin and dextrose broadly.

FAQs

Is clindamycin in 5% dextrose the same as clindamycin phosphate injection?

It is a diluted intravenous presentation of clindamycin phosphate injection. The active drug is clindamycin phosphate, while 5% dextrose is the infusion vehicle.

Can clindamycin phosphate be mixed with normal saline instead of dextrose?

Clindamycin phosphate injection is compatible with several common intravenous diluents, including 0.9% sodium chloride, subject to product labeling and concentration limits.[1] A saline product is commercially useful for patients who should avoid additional dextrose.

Does clindamycin in 5% dextrose require a preservative?

A single-dose sterile intravenous premix generally does not require a preservative. Avoiding preservatives can simplify toxicology, compatibility, and hospital acceptance.

What is the main regulatory pathway for a generic clindamycin premix bag?

An ANDA may be appropriate where the proposed product is pharmaceutically equivalent to the reference product and meets applicable requirements. A materially different formulation, container, or labeling strategy may require a 505(b)(2) application or another pathway determined by FDA product-specific guidance.

What is the most defensible patent strategy for a new clindamycin premix?

The strongest strategy is to claim a specific stable formulation or container system supported by comparative data. Process patents and trade secrets covering sterile manufacture, oxygen control, particulate reduction, and packaging integrity can supplement composition claims.

References

1. U.S. Food and Drug Administration. (2023). Clindamycin phosphate injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-content-and-format

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm